Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Clinical trial NCT05746728 · UNKNOWN
Trial details
- NCT number
- NCT05746728
- Sponsor
- Huihua Xiong
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-01
- Primary completion
- 2024-08-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.